Skip to content

US · SENS · MEDICAL - DEVICES

Senseonics Holdings, Inc. (SENS) intrinsic value and stock valuation

$8.02as of 2026-11-21 · Mkt cap 216.49M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Senseonics Holdings, Inc. DCF and intrinsic value

InvestorsCraft values SENS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SENS’s statements →

Senseonics Holdings, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Germantown, MD 20876-7005 senseonics.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$35.3M+48.1% 5y CAGRd
20132025
Net income
-$-69.11M
20132025
Free cash flow
-$-60.24M
20132025
Total equity
$61.1M
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$35.3M$22.5M$22.4M$16.4M$13.7M
Operating income-$-68.34M-$-74.84M-$-75.6M-$-68.63M-$-57.18M
Net income-$-69.11M-$-78.62M-$-60.39M$142.1M-$-302.47M
EPSd-$-1.66M-$-2.5M-$-2.13M$4.6M-$-14.32M
Operating cash flow-$-59.13M-$-60.47M-$-70.16M-$-66.31M-$-56.08M
Capital expenditure-$-1.12M-$-2.24M-$-350K-$-310K-$-210K
Free cash flow-$-60.24M-$-62.7M-$-70.51M-$-66.62M-$-56.29M
Total assets$126.3M$100.4M$138.2M$177.7M$198.9M
Total debt$41.4M$61.1M$47.8M$75.4M$64.2M
Net debt$820K-$-13.54M-$-27.93M$39.6M$30.8M
Total equity$61.1M-$-16.55M$35.8M-$-2.58M-$-185.53M
Cash and short-term investments$94M$74.6M$109.5M$144M$129.9M
Income statement
20252024202320222021
Revenue$35.3M$22.5M$22.4M$16.4M$13.7M
Cost of revenue$19.5M$21.9M$19.3M$13.7M$14.5M
Gross profit$15.8M$530K$3.09M$2.73M-$-810K
Research and development expenses$31.6M$41.1M$48.8M$39.7M$27.2M
Selling, general and administrative expenses$52.5M$34.2M$29.9M$31.6M$29.2M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$84.1M$75.4M$78.7M$71.4M$56.4M
Cost and expenses$103.6M$97.3M$98M$85M$70.9M
Interest income$4.2M$4.5M$5.36M$1.82M$240K
Interest expense$4.95M$8.44M$11.1M$18.7M$16.7M
Depreciation and amortization$1.51M$1.48M$1.28M$980K$1.24M
Ebitda-$-62.65M-$-68.7M-$-48.01M$161.8M-$-284.51M
Operating income-$-68.34M-$-74.84M-$-75.6M-$-68.63M-$-57.18M
Total other income/expenses, net-$-780K-$-3.77M$15.2M$210.8M-$-245.29M
Income before tax-$-69.11M-$-78.62M-$-60.39M$142.1M-$-302.47M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-69.11M-$-78.62M-$-60.39M$142.1M-$-302.47M
Weighted average shares outstanding$41.7M$31.5M$28.4M$23.4M$21.1M
Weighted average diluted shares outstanding$41.7M$31.5M$28.4M$30.9M$21.1M
Balance sheet
20252024202320222021
Cash and short-term investments$94M$74.6M$109.5M$144M$129.9M
Net receivables$12.4M$8.08M$6.6M$2.79M$2.42M
Inventory$6.7M$4.42M$8.78M$7.31M$6.32M
Total current assets$117.5M$91.4M$130M$161.2M$144.4M
Property, plant and equipment, net$4.2M$3.59M$1.18M$1.11M$1.31M
Goodwill and intangible assets$800K$480K$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$12.3M$51.9M
Total non-current assets$8.74M$9M$8.19M$16.5M$54.5M
Total assets$126.3M$100.4M$138.2M$177.7M$198.9M
Accounts payable$4.06M$3.21M$4.57M$420K$1.2M
Short-term debt$500K$20.6M$370K$16.3M$3.83M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$24.4M$38.9M$17.3M$31.5M$18.4M
Long-term debt$40.9M$40.5M$47.4M$59.1M$60.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$40.9M$78.1M$85.2M$148.8M$366.1M
Capital lease obligations$5.29M$6.21M$6.58M$3.41M$1.48M
Total liabilities$65.2M$117M$102.4M$180.3M$384.5M
Common stock$40K$590K$530K$480K$450K
Retained earnings-$-1.02B-$-947.87M-$-869.26M-$-808.87M-$-950.99M
Accumulated other comprehensive income (loss)$70K$0.00-$-10K-$-680K-$-210K
Total equity$61.1M-$-16.55M$35.8M-$-2.58M-$-185.53M
Total investments$53.8M$0.00$33.8M$120.5M$148.3M
Total debt$41.4M$61.1M$47.8M$75.4M$64.2M
Net debt$820K-$-13.54M-$-27.93M$39.6M$30.8M
Cash flow statement
20252024202320222021
Net income-$-69.11M-$-78.62M-$-60.39M$142.1M-$-302.47M
Depreciation and amortization$90K$1.48M$1.28M$980K$1.24M
Stock-based compensation$10.2M$9.22M$8.67M$8.62M$9.03M
Change in working capital-$-3.28M$860K-$-3.97M-$-2.47M-$-1.5M
Accounts receivable-$-6.76M-$-2.7M-$-2.19M-$-480K$1.01M
Inventory-$-2.98M$700K-$-1.64M-$-990K-$-1.04M
Accounts payable$1.22M-$-1.83M$2.3M-$-790K-$-560K
Net cash provided by operating activities-$-59.13M-$-60.47M-$-70.16M-$-66.31M-$-56.08M
Investments in property, plant and equipment-$-1.12M-$-2.24M-$-350K-$-310K-$-210K
Acquisitions, net$0.00$0.00$0.00-$-27.19M$210K
Net cash used for investing activities-$-53.42M$32.8M$89.7M$26.9M-$-148.75M
Common stock issued$100.7M$18.4M$7.38M$34.2M$200.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$78.2M$26.8M$20.4M$41.8M$220.1M
Net change in cash-$-34.36M-$-800K$39.9M$2.33M$15.3M
Cash at end of period$40.6M$74.9M$75.7M$35.8M$33.5M
Operating cash flow-$-59.13M-$-60.47M-$-70.16M-$-66.31M-$-56.08M
Capital expenditure-$-1.12M-$-2.24M-$-350K-$-310K-$-210K
Free cash flow-$-60.24M-$-62.7M-$-70.51M-$-66.62M-$-56.29M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Senseonics Holdings, Inc.

        Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.

        CEO
        Timothy T. Goodnow
        Employees
        130
        Beta
        0.99

        Explore

        Frequently asked questions

        What is the intrinsic value of Senseonics Holdings, Inc. (SENS)?

        Senseonics Holdings, Inc. (SENS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SENS undervalued?

        SENS trades at a price of $8.02 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.